Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales ...

Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” ...

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.

Cormark lowered their Q2 2025 earnings per share estimates for Torex Gold Resources in a research report issued on Monday, ...

Torex Gold Resources Inc . (TSX: TXG) stock rose Thursday after RBC Capital Markets raised its price target to C$65 from C$60, citing exploration potential and the ongoing ramp-up of the company’s ...

Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds.

The average of price targets set by Wall Street analysts indicates a potential upside of 43.1% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa ...

10x Genomics (TXG) closed the last trading session at $8.86, gaining 7.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...